From Nasdaq: 2025-02-10 08:35:00

Earnings season gives investors a look at a company’s past performance, but future decisions should be based on guidance for upcoming quarters. Despite lower-than-expected earnings from some companies, analysts see potential in stocks like Eli Lilly & Co. (LLY) and AbbVie Inc. (ABBV) due to strong drug sales and promising pipelines.

Eli Lilly & Co. (LLY) reported earnings per share of $5.32, surpassing last year’s numbers but missing analyst expectations. Despite lower prices for its GLP-1 drug, Mounjaro, strong sales contributed to revenue growth. Analysts predict a 13.6% upside for LLY stock with a dividend that has increased by 103% in the last five years.

AbbVie Inc. (ABBV) posted revenue that beat estimates but had lower-than-expected earnings per share due to Humira competition. However, sales from other drugs like Skyrizi and Rinvoq are offsetting declines. FDA approval for Emblaveo is a positive sign for future revenue growth, leading analysts to be optimistic about ABBV stock.

Las Vegas Sands Inc. (LVS) fell short on earnings but exceeded revenue estimates. Analysts are optimistic about increased casino revenue as the company expands its hotel capacity in Macao and Singapore. Although facing risks, LVS stock has a bullish consensus price target of $59.58, representing a 38.5% increase from its closing price on February 7, 2025.



Read more at Nasdaq:: These Stocks Missed on Earnings, But Will Rebound Next Quarter